Format

Send to

Choose Destination
Eur Urol. 2017 Nov 2. pii: S0302-2838(17)30839-4. doi: 10.1016/j.eururo.2017.09.029. [Epub ahead of print]

Updated Guidelines for Metastatic Hormone-sensitive Prostate Cancer: Abiraterone Acetate Combined with Castration Is Another Standard.

Author information

1
Department of Urology, University Hospital, St. Etienne, France. Electronic address: nicolas.mottet@chu-st-etienne.fr.
2
Clinical Trials Unit, University of Warwick, UK; Department of Urology, Medical University of Vienna, Austria.
3
Patient Advocate, Hasselt, Belgium.
4
Faculty of Health and Wellbeing, Sheffield Hallam University, Sheffield, UK.
5
Department of Oncology/Hematology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland; University of Bern, Switzerland.
6
Department of Surgery, Central Clinical School, Monash University, Melbourne, Australia.
7
Academic Urology Unit, University of Aberdeen, Aberdeen, UK; Department of Urology, Aberdeen Royal Infirmary, Aberdeen, UK.
8
Department of Urology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
9
Hospices Civils de Lyon, Radiology Department, Edouard Herriot Hospital, Lyon, France; Université de Lyon; Université Lyon 1, Faculté de Médecine Lyon Est, France.
10
Royal Liverpool and Broadgreen Hospitals NHS Trust, Liverpool, UK.

Abstract

Addition of docetaxel to androgen deprivation therapy (ADT) was recommended for patients with newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC), who are fit enough to receive docetaxel. Two recently published trials showed that the addition of abiraterone acetate plus prednisone to ADT has a clear survival benefit and acceptable overall tolerance, and should be considered as another standard of care for newly diagnosed mHSPC.

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center